MedTrace Logo

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine

NCT02974153 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1121

Last updated 2020-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

Conditions

  • Migraine Disorders

Interventions

BIOLOGICAL

ALD403 (Eptinezumab)

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-11-30
Completion
2018-04-30

Countries

  • United States
  • Belgium
  • Czechia
  • Denmark
  • Georgia
  • Germany
  • Hungary
  • Italy
  • Russia
  • Slovakia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974153 on ClinicalTrials.gov